Company Information
CIN
Status
Date of Incorporation
19 October 1949
State / ROC
Mumbai / ROC Mumbai
Last Balance Sheet
31 March 2023
Last Annual Meeting
10 August 2023
Paid Up Capital
253,700,000
Authorised Capital
576,000,000
Directors
Anand Trimbak Kusre
Director/Designated Partner
about 2 years ago
about 2 years ago
Pranay Premchand Godha
Director/Designated Partner
over 2 years ago
over 2 years ago
Premchand Gigalal Godha
Director/Designated Partner
over 2 years ago
over 2 years ago
Kamal Kishore Seth
Director/Designated Partner
over 2 years ago
over 2 years ago
Narendra Mairpady
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Prashant Premchand Godha
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Ajit Kumar Jain
Director/Designated Partner
over 6 years ago
over 6 years ago
Dev Parkash Hemraj Yadava
Director/Designated Partner
over 6 years ago
over 6 years ago
Harish Pandurang Kamath
Nodal Officer
about 32 years ago
about 32 years ago
Past Directors
Manisha Premnath
Director
over 10 years ago
over 10 years ago
Ramakanta Panda
Director
over 12 years ago
over 12 years ago
Vishnu Atmaram Gore
Director
over 22 years ago
over 22 years ago
Ramachandran Thembalath Moothedath Ramankutty Nair
Director
over 31 years ago
over 31 years ago
Babu Lal Jain
Director
over 37 years ago
over 37 years ago
Madhukar Ramchandra Chandurkar
Managing Director
about 50 years ago
about 50 years ago
Patents
An improved process for manufacturing hydrogen sulfate salt of (+)-(S)-alpha-2-(chlorphenyl)-6,7-dihydrothieno [3,2-C] pyridine-5 (4-H)-acetic acid methyl ester, commonly known as Clopidogrel hydrogen sulphate, in two crystalline forms viz: Form-I and Form-II is disclosed herein.
The invention discloses preparation of novel intermediates, Artemisinic acid of formula II and Dihydroartemisinic acid of formula Ila useful in the preparation of Artemisinin derivatives by providing pure Amorphadiene- 4,5-epoxide.
A process for synthesis and isolation of pure Losartan Potassium (I ) which
comprises,
i) reacting Trityl Losartan (III) in a primary alcohol with potassium t-
alkoxide ii) concentrating the reaction mass to remove the primary alcohol
completely or partially iii) isolating the said pu...
The invention discloses novel anhydrous crystalline form of S-(+) Hydroxychloroquine sulfate and process for preparing anhydrous crystalline form of S-(+) Hydroxychloroquine sulfate and its characterization.
Disclosed herein is a process for preparation of Iguratimod. More particularly, the invention discloses novel process for preparation of intermediate, 3-amino-4-phenoxyanisole, useful in the preparation of Iguratimod.
A pharmaceutical composition comprising Hydroxychloroquine, its enantiomer or a pharmaceutically acceptable salt thereof or its combinations with at least one drug selected from the group of Angiotensin receptor blockers and Angiotensin converting enzyme inhibitors for treatment and/or prophylaxis of Kidney Diseases...
Disclosed herein is an improved process for preparation of Nabumetone which includes reduction of 4-(6-methoxy-2-naphthyl)-3-buten-2-one with hydrogen in presence of Nickel catalyst coated with hydrogenated vegetable oil or hydrogenated palm stearine in presence of suitable solvent.
The present invention discloses a novel recovery and recycling process of unwanted enantiomers of 2-aminopropyl indoline derivatives, useful intermediates, particularly, for preparation of Silodosin or salts thereof. The present invention also provides novel compounds of Formula-II Formula-III, Formula-IV and Formul...
The present invention discloses a new process for preparation of Nebivolol or it’s pharmaceutically acceptable salt. More particularly, the invention discloses an improved economical process for the preparation of intermediate, 6-fluoro-3,4-dihydro-2H-1-benzopyran-2-carboxaldehyde of Formula – II, converting the 6-f...
Disclosed herein is a novel recovery and recycling process of racemic 4-(4-dimethylamino)-1-(4’-fluorophenyl)-1-(hydroxybutyl)-3-(hydroxymethyl)-benzonitrile (hereinafter referred as cyanodiol). The racemic cyanodiol is an intermediate useful for preparation of Citalopram, Escitalopram or pharmaceutically acceptable...
The present invention discloses a pharmaceutical combination comprising Hydroxychloroquine and a DPP-IV inhibitor or their pharmaceutically acceptable salts thereof, for preventing, slowing the progression of, delaying, improving, restoring, or treating a condition or a disease resulting from metabolic disorders.
...
The present invention relates to a preparation method for l-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy) ethyl] amino]-2-propanol and its salts.
Process for preparing 4-chloro-substituted pyridine intermediates of formula I, useful for preparation of pyridinylmethylsulphinyl beneimidazole compounds, especially Rabeprazole is disclosed herein. The invention, further describes process for predation of Rabeprazole sodium of high purity in a reproducible & consi...
The present invention relates to an improved process for preparation of (+)-(S)-alpha-2-(chlorphenyl)-6, 7-dihydrothieno [3,2-C] pyridine-5 (4-H)-acetic acid methyl ester, commonly known as Clopidogrel . The invention is characterized by process improvements in resolution of racemic Clopidogrel and recycling of reso...
An improved for the synthesis of fluconazole comprising reacting the compound of formula II(X=F)with trimethyl sulphoxonium iodide in presence of alkali metal hydroxide and phase transfer catalyst in a solvent combination of toluence and water;isolating the resulting oxirane compound of Formula III and reacting the ...
Disclosed herein is modified release composition useful for the treatment of epilepsy (anti-convulsant, help control some types of seizures, post-traumatic stress disorder (ptsd) and/or borderline personality disorder (bpd), bipolar disorders and unipolar depressions) comprising lamotrigine or pharmaceutically accep...
The present invention discloses novel polymorphic forms of perindopril erbumine that are alcohol solvates, more particularly novel morphologically identical forms of perindopril erbumine salt characterized by powder X-ray diffraction pattern. The present invention further discloses processes for preparing such form ...
The present invention provides a process for preparation of ramipril comprising reacting an acid addition salt of bicyclic amino ester of formula (VII) with N-(l-S carboethoxy)-3-phenyl-propyl-L-alanine in presence of dicyclohexylcarbodimide and 1 -hydroxybenzotriazole in a suitable solvent medium.
...
Disclosed herein is a process for manufacture of glimepiride (Formula I) and its intermediates that comprises a 4-pyrrolidinopyridine or 4-(dimethylamino)pyridine catalyzed reaction of compound of Formula IX, wherein R= lower alkyl group, with trans 4-methyl cyclohexyl amine in an organic solvent to form glimepiride...
Disclosed herein is novel process of Atovaquone, which process includes reacting 1,4-naphthoquione with trans-4-(4-chlorophenyl) cyclohexane carboxyane carboxylic acid followed by halogenation to obtain dihalo-compound, further dehydrohalogenation of dihalo-compound to obtain monohalogeno-compound, and hydrolysis of...
An improved process of manufacture of Aceclofenac, an NSAID, which essentially involves modification of reaction parameters such as temperature and pressure, selection of non-reactive and solvents as the reaction medium, and optimization of regent quantities in the debenzylation of aceclofenac benzylester. This modi...
The present invention discloses a process for preparation of compound of Formula-V or it"s pharmaceutically acceptable salts thereof by reacting enantiomerically enriched (R)-isomer of compound of formula-III-B or salts.
wherein, Rl and R2 independently of one another denote H, linear or branched (C1-C8)-alkyl, ...
Disclosed herein is an economic process for preparation of piperaquine tetra phosphate tetra hydrate comprises reacting 4,7-dichloroquinoline with piperazine in C1 to C4 alcohols to obtian a compound of formula II and isolating it substantially free from dimmer impurity of formula IV, heating the compound of formul...
The present invention discloses novel process for preparation of stable fixed dose combination comprising Metoprolol succinate and Ramipril which provides dual release of both active ingredients.
21
Disclosed herein is a procss for preparation of carvedilol substantially free from its bisimpurity comprises the reaction of 4-(2,3-epoxypropoxy)carbazole and 2-(2-methoxyphenoxy)ethylamine in a polar aprotic solvent media;followed by isolation of carvediol from the reaction mass as an acid addition salt and subsequ...
Disclosed herein is an industrial preparation of Quetiapine by the reaction of 11-piperazinyldibenzo[b,f][1,4]-thiazepine or its salt with 2-(2-chloroethoxy) ethanol in presence of an organic base under neat condition to form 11-[4-{2-(2-hydroxyethoxy)ethyl}-1-piperzinyl] dibenzo [b,f][1,4]-thiazepine. The quetiapin...
This invention relates to sustained release anti-malarial formulation of Primaquine or its pharmaceutically acceptable salt with reduced side effects typically associated with the dosing of primaquine and method for preparing the same. The preparation of formulation involves use of a hydrophilic polymer such as, hyd...
The invention provides a process for preparation of hydroxyzine, which process includes reacting haloethoxyethanol with piperazine derivative of formula II or its salts in an aqueous phase.
The invention discloses a stable, solid, oral pharmaceutical composition comprising a combination of two incompatible anti-malarial compounds, artesunate and amodiaquine with pharmaceutically acceptable excipients, in the form of tablet-in-tablet, and the process thereof.
The oximination/cyclization of 2-(4-chlorobenzoyl)benzoic acid with hydroxylamine hydrochloride in presence of molar quantities of inorganic base in water or in alcoholic solvents to form 4-(4’-chlorophenyl)-5,6-bent-oxazine-l-one Formula (8) in high yield and purity; reduction of latter with zinc metal and acetic a...
Disclosed herein is novel synergistic pharmaceutical compositions comprising oral arteether like β arteether(artemotil) or a/β arteether in a fixed dose combination with other antimalarials selected from the group consisting of piperaquine, lumefantrine and curcumin along with pharmaceutical excipients/carriers usef...
A process for the resolution of isomeric tramadol mixtures comprising: providing a purification stock comprising both cis and trans tramadol; contacting the purification stock with an acid under conditions effective to form an acid salt of the cis and trans tramadol in the purification stock; and separating the cis ...
The present invention discloses novel processes for preparing optically active sulphoxide compounds of formula I by asymmetric oxidation of prochiral sulphide compounds of Formula II. More particularly, the invention discloses processes for preparation of optically active proton pump Inhibitors (PPIs) or their optic...
The present invention discloses novel processes for preparing optically active sulphoxide compounds of formula I by asymmetric oxidation of prochiral sulphide compounds of Formula II. More particularly, the invention discloses processes for preparation of optically active proton pump Inhibitors (PPIs) or their optic...
The present invention discloses novel processes for preparing optically active sulphoxide compounds of formula I by asymmetric oxidation of prochiral sulphide compounds of Formula II. More particularly, the invention discloses processes for preparation of optically active proton pump Inhibitors (PPIs) or their optic...
PROCESS FOR PREPARATION OF CETIRIZINE/LEVOCETIRIZINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
The present invention discloses an improvement of our main invention filed as application number 760/MUM/2007. The improvement includes conversion of novel intermediates of Formula II and Formula III into isomeric mixture of atovaquone. The improvement further includes epimerization of isomeric mixture of atovaquone...
Disclosed herein is a novel synergistic pharmaceutical composition comprising hydroxychloroquine with insulin sensitizing agents and lipid lowering agents such as statins along with pharmaceutical excipients/carriers useful in treating Non-Alcoholic Fatty Liver Disease
A process for preparation of gabapentin comprising a step of obtaining 1, 1cyclohexane diacetic acid monoamide from 1, 1-cyclohexane diacetic acid anhydride, wherein said reaction is characterized by the use of ammonia precursor or pre-generated ammonia isopropanol solution. The invention further preparation of gaba...
Process for the production of high purity perindopril erbumine in alpha crystalline form, which is in a class of medication called angiotensin-converting enzyme (ACE) inhibitors is dislosed.
A process for producing Fenofibrate Comprising: reacting a phenol derivative represented by formula (II), wherein R = H or alklai metal with Haloisobutyric acid isopropyl ester for Formula III, in the presence of a phase transfer catalyst is disclosed herein.
The present invention relates to new compounds, process for preparing the compounds of the present invention that are useful for preparing optically active cetirizine; process for preparing optical isomers of cetirizine or its pharmaceutical salts; and process to racemize & recycle the optical isomers of cetirizine ...
Disclosed herein do fixed dose pharmaceutical compositions comprise: a) Hydroxychloroquine b) an antidiabetic drug selected from the group consisting of Sulphonylureas, Biguanides or Thiazolidinediones and c) at least one pharmaceutical excipients/carrier, useful in the treatment of diabetes mellitus.
24 SEP ZQ06
...
Disclosed is a single-pot manufacturing process for the preparation of a pharmaceutical drug, Nabumetone, characterized by its robustness, simple to operate, cost effectiveness and environmental friendliness.
Disclosed herein is vovel crystalline froms of Valsartan namely, a crystalline form designated as From A, and its solvates thereof, novel crystalline form of Valsartan desiganted as From B and solvates thereof, novel crystalline from of Valsartan designated as From C and solvates thereof , novel crystalline form of ...
Disclosed herein is a cost effective, high yielding, reproducible method for the manufacture of alendronic acid or its salt such as sodium alendronate from inexpensive and readily available pyrrolidone using phosphonating agents such as PCl3 in the presence of acids such as sulphonic acids, sulphuric acid or phospho...
The present invention discloses a process for preparation of a stable pharmaceutical composition comprising of a combination of an angiotensin II receptor antagonist such as losartan potassium and a diuretic such as chlorthalidone and its formulation thereof. This combination drug product is useful in the treatment ...
Disclosed herein is an improved process for preparation of clopidogrel base or its bisulphate salt which comprises an intermediate step of obtaining clopidogrel free base from clopidogrel acid salt in non-aqueous conditions using a base. Also, disclosed methods of recovery and recycling of camphorsulphonic acid from...
The present invention relates to a novel polymorphic form of Atovaquone. More particularly, it relates to novel crystalline form, that has improved solubility and other bulk characteristics suitable for pharmaceutical application. The present invention also relates to processes for preparing such form of Atovaquone ...
The present invention relates to a novel method for synthesis of 4"-[(l ,4"-dimethyl-2"-
propyl-[2,6"-bi-l/f)benzimidazol]-l-yl)methyl]-[1,1-biphenyl]-2-carboxylic acid,
commonly known as Telmisartan. The invention further relates to novel intermediate compounds useful in the synthesis of Telmisartan, and process ...
A process for the formation of high purity sulphonyl urea compounds in high throughput conditions. The sulphonyl urea compounds are preferably the pharmaceutically useful anti-diabetic drugs such as Glimepiride, Gliclazide, Glipizide, Glibenclamide, Glibornuride, Glisoxepide etc, where the purity & economy of the co...
The present invention describes an improved industrial process for crystallizing out polymorph 'Form F of (+) clopidogrel hydrogen sulphate (also called clopidogrel hydrogen sulphate) in solvent selected from methylethyl ketone, tertiarybutyl methylether, cyclopentylmethyl ether, dipropylglycolether, dibutylglycol e...
The present invention describes an improved industrial process for crystallizing out
polymorph ‘Form I’ of (+) clopidogrel hydrogen sulphate (also called clopidogrel
hydrogen sulphate) in solvent selected from methylethyl ketone, tertiarybutyl
methylether, cyclopentylmethyl ether, dipropylglycolether, dibutylglyc...
Novel diasteriomeric tartaric acid salts of atenolol namely,(2S)-1-isopropylamino-3-[4-(2-acetamido)phenoxy]-2-propanol-(2S,3S)-O,O-di-p-toluoylatartrate, (2R)-1-isopropylamino-3-[p-(2-methoxyethy)phenoxy]-2-propanol-(2R,3R)-O,O-di-p-toluoyltartrate and their use in the pripartion of optically active atenolol by a ...
Disclosed herein is a novel crystalline form of Chlorthalidone designated as Form II, its solvates thereof; the processes for their preparation; isolation of this new form; and its use in pharmaceutical preparations. The present invention further discloses the novel processes for preparation of From I and its charac...
The present invention discloses a stable semi-solid combination of therapeutically effective amounts of a non-steroidal anti-inflammatory drug, aceclofenac with a counter irritant agent, methyl salicylate and a skin penetrator, menthol suitable for topical administration. The invention further relates to the incorpo...
Disclosed herein is an industrial process for preparation of Quetiapine by the reaction of ll-piperazinyldibenzo[b,f][l,4]-thiazepine or its salt with 2-(2-chloroethoxy)ethanol in presence of an inorganic base in aqueous condition to form ll-[4-{2-(2-hydroxyethoxy) ethyl}-1-piperazinyl] dibenzo [b,f]-[l, 4]thiazepin...
A one-pot industrial process for preparing 1,2,3,9-tetrahdro-9-methyl-3-[(2-methyl-1H-imidazole-1-y)methyl]-4H-carbozol-4-one of Formula-I from 1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one of Formula-IV involves reaction of Formula IV with HNR1 R2 salt and paraformaldehyde,where R1,R2 are independently alkyl groups...
A novel process for an extended release oral solid dosage formulation of metoprolol succinate is provided which includes an extended release polymer base retardant coating. In the present invention metoprolol succinate tablets comprising of strengths varying from 12.5 to 200mg are prepared via a wet granulation meth...
This invention discloses a novel, stable delayed release antimalarial composition of a pharmaceutically effective amount of antimalarial agent from the artemisinin group such as B-arteether. Since the antimalarial agent is unstable in stomach, the dosage form is designed such that the active ingredient is released a...
The present invention deals with a novel process for preparation of fixed dose combination of two actives in a stable tablet - in - tablet pharmaceutical composition, prepared with dual release drug absorption system technology, comprising angiotensin II receptor antagonist such as losartan potassium and a beta-sele...
The present invention describes an improved industrial process for crystallizing out polymorph "Form I" of (+) clopidogrel hydrogen sulphate (also called clopidogrel hydrogen sulphate) from an organic solvent or liquid comprising two or more functional groups or their mixtures, in a reproducible manner without detec...
A process for the preparation of pharmaceutical composition in the form of bilayered tablet comprising pharmaceutically acceptable combination of Cephalosporin antibiotics such as Cefadroxil incorporated as sustained release component and probiotic bacteria such as lactobacillus incorporated as conventional release ...
Disclosed herein are stable pharmaceutical compositions of drug with low water solubility. Specifically, the present invention discloses stable pharmaceutical compositions of Isotretinois and process threof.
An improved process for manufacturing hydrogen sulfate salt of (+)-(S)-alpha-2-(chIorphenyl)-6,7-dihydrothieno [3,2-C] pyridine-5 (4-H)-acetic acid methyl ester, commonly known as Clopidogrel hydrogen sulphate, in two crystalline forms viz: Form-I and Form-II is disclosed herein.
13 AUG 2008
16
...
The present invention discloses a process for the preparation of the antidepressant drug, Escitalopram, chemically designated as S-(+)-1-(3-dimethylaminopropyl)-l-(4-fluoro-phenyl)-I,3-dihydroisobenzofuran-5-carbonitrile (Formula-I), or it"s pharmaceutically acceptable salts. The invention further discloses improvem...
The present invention discloses a cost-effective, industrially feasible process for preparation of carvedilol of high HPLC purity (>99.5%), absolutely free from bisimpurity. The said process comprises, reacting 4-hydroxy carbazole with epichlorohydrin in presence of aluminium or Lewis acid; further the resultant 4-(...
Disclosed herein is a process for preparation of mycophenolic acid which
comprises; a) culturing a mycophenolic acid producing microorganism; b) adjusting the pH of the fermentation culture obtained in step a) to acidic; c) recovering the mycelia by filtration or other means; d) leaching the mycelia with an organi...
A once-a-day, stable pharmaceutical composition of Zolpiden tartrate for improving maintenance of sleep though out 8 hrs in the form of Inlay comprising an inner extended release core and an outer immediate release coat, wherein said hydrophilic polymeric coating is effective in delaying the release profile on admin...
The present invention discloses novel synergistic pharmaceutical composition comprising Colchicine in combination with NSAIDs selected from the group comprising Etodolac, aceclofenac, Indomethacin, Nabumetone, Etoricoxib, Celecoxib, Diclofenac, Piroxicam along with pharmaceutical excipients/ carriers useful in treat...
The present invention relates to a method of ameliorating the drawbacks of anti-platelet drug named Clopidogrel. The method of the present invention comprises administration of an oxo-metabolite of clopidogrel or its derivative of the formula II in its free or pharmaceutically acceptable salt form for alleviating th...
A. substantially pure isomer of an intermediate metabolite of clopidogrel, namely, (7aS,2'S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment of thrombo-embolism and/or cardiovascular diseases.
The present invention discloses a short, efficient process for preparation of antidiabetic drug Glipizide of formula IV. The invention also discloses preparation of N-[2-[4-(aminosulfonyl)phenyl]ethyl]-5-methylpyrazine-carboxamide of formula-I, an intermediate used in the synthesis of the Glipizide comprising reacti...
The invention relates to an oral pharmaceutical composition containing active ingredients of poor aqueous solubility, more specifically, antiparasitic and antipneumocystic drug Atovaquone alone or in combination with Proguanil.
Disclosed herein are stable dual release pharmaceutical compositions used for treatment of hypertension, chronic stable angina and other related cardiovascular diseases comprising combination of therapeutically effective amount of a synthetic beta-selective (cardioselective) adrenoreceptor blocking agent Metoprolol ...
The present invention discloses stable pharmaceutical compositions comprising pharmaceutically acceptable acid addition salt of vasodilator such as Amlodipine and acid addition salt of a synthetic beta-selective adrenoreceptor blocking agent Metoprolol Succinate formulated as oral solid dual release pharmaceutical c...
A heterogeneous catalyst such as disordered, mesoporous, manganosilicate molecular sieves having pore size in the range of 20˚A to 60˚A and a process for the preparation of the same are disclosed in this specification. This invention further provides application of said heterogeneous catalyst for oxidation of alcoho...
Disclosed herein is a novel crystalline form of 3-Benzyl - 6-trifluromethyl - 7 - sulfamyl -3,4-dihydro - 1,2,4- benzothiadiazine - 1,1- dioxide, designated as 'Form II' and processes for preparation thereof. The invention further discloses a new process for preparation and isolation of crystalline Form I.
...
The present invention discloses stable pharmaceutical composition comprising beta-lactam antibiotic, cefotaxime and beta-lactamase inhibitor, sulbactam in parentral form. In particular, this invention describes the compositions of cefotaxime salt and sulbactam salt in varying strengths which are useful for the terat...
The present invention discloses a method to prevent and/or to delay the onset of developing diabetes as well as a treatment of drug induced pre-diabetic or diabetic condition in a human who is treated or likely be treated with a HMG-CoA reductase inhibitor (hereinafter also referred as Statin(s). The method of the p...
The invention relates to novel complex(es) of an antipneumocystic compound and an antimalarial compound, process for their preparation, pharmaceutical compositions and methods of using said complexes or compositions for the treatment and/or prophylaxis of parasitic infections.
The present invention discloses an improved process for preparation of substantially pure Norethisterone acetate.
The present invention discloses a novel process for the preparation of (+)-(S)-alpha-2-(chlorophenyl)-6,7-dihydrothieno[3,2-C]pyridine-5-(4-H)-acetic acid methyl ester hydrogen sulphate of Formula I, commonly known as Clopidogrel bisulphate. Particularly, the invention discloses preparation of Clopidogrel bisulphate...
The present invention discloses a novel process for preparation of substantially pure valproic acid and it’s sodium salt. The invention particularly discloses preparation of key intermediates, monopropyl and dipropyl malonic esters without using solvent.
“IMPROVED PROCESS FOR PREPARATION OF NEBIVOLOL AND IT’S SALTS”
ABSTRACT:
The present invention discloses a new process for preparation of Nebivolol or it’s pharmaceutically acceptable salt. More particularly, the invention discloses an improved economical process for the preparation of intermediate, 6-fluoro-3,4...
Disclosed herein is an improved and efficient process for preparation of antidiabetic drug Glipizide of formula-IV. Particularly, the invention discloses preparation of N-[2-[4-(aminosulfonyl)phenyl]ethyl]-5-methylpyrazine-carboxamide of formula-I, an intermediate useful in the synthesis of Glipizide ...
The present invention discloses a novel heterogeneous oxidation catalyst for selective oxidation of alcohol to aldehydes in various substrates. This catalyst comprises a heteropoly acid like phosphomolybdic acid (PMA) supported on vanadium-aluminum mixed oxide. The present invention also discloses methods of...
1. A stable controlled release once-a-day pharmaceutical composition in solid dosage form comprising aceclofenac, dispersed in release controlling polymeric matrix along with pharmaceutically acceptable excipients; wherein the said polymeric matrix comprises of hydroxypropylmethyl cellulose, ethyl cellulose ...
The present invention relates to a compound of general formula IVA, when R is selected from subsituted or unsubtituted arylalkyl groups; and HA represents an acid capable of forming a salt.
Disclosed herein is a new process for preparation of Iguratimod of formula-I. More particularly, the invention discloses process for preparation of intermediate of formula-II useful in the preparation of Iguratimod.
Disclosed herein is a process for the preparation of angiotensin-II receptor antagonist drug, Telmisartan. The invention particularly discloses process for the preparation of ortho tolyl benzyl n-butyl ester by hydrolysis of ortho tolyl benzonitrile followed by esterification in n-butanol solvent and further convers...
The present invention discloses a novel common analytical method and system by Reversed Phase High Performance Liquid Chromatography (RP-HPLC) for detection and quantification of melamine present in various Active Pharmaceutical Ingredients (APIs). Particularly, the present invention discloses a unique, common analy...
The present invention discloses a novel process for the preparation of Diphenoxylate Hydrochloride, using novel intermediate, 4-Phenylpiperidine-4-carboxylic acid hydrobromide.
4-Phenylpiperidine-4-carboxylic acid hydrobromide.
The present invention discloses a novel process for the preparation of a hormone, Ethinyl estradiol. Particularly, the invention discloses the preparation of a high purity Ethinyl estradiol using a novel Ethinyl estradiol-dimethyl formamide solvate having 1:1 molecular ratio.
The present invention discloses a novel process for the preparation of Leflunomide. More particularly, the invention discloses an improved process for preparation of the intermediates, viz., 4-(trifluoromethyl)anilne and 5-methylisoxazole-4-carboxylic acid useful for the preparation of Leflunomide.
...
The present invention discloses stable oral pharmaceutical composition containing therapeutically effective amount of (7aS,2’S)-2-oxoclopidogrel and/or its salts or derivatives, in combination with pharmaceutically acceptable adjuvants or carriers. More particularly, the present invention discloses highly pure (7aS,...
The present invention discloses a process for the preparation of angiotensin-II receptor antagonist drug, Telmisartan and its pharmaceutically acceptable salts.
The present invention discloses Atovaquone prodrugs, process for the preparation of said prodrugs and pharmaceutical compositions comprising Atovaquone prodrugs. Atovaquone prodrugs of the present invention can be used alone, or co-administered orally or parenterally as fixed dose or as separate dosage form in combi...
This invention discloses an improvement in process for preparation of Losartan Potassium. More specifically, this invention discloses a commercial process for preparation of high purity Losartan potassium having azido impurity within the TTC limits.
The present invention discloses a novel pharmaceutical composition of Atovaquone or Proguanil in combination with Atovaquone. More particularly, the invention discloses long- acting injectable composition which provides sustained depot effect of Atovaquone & Proguanil and offering prolonged therapeutic and prophylac...
Registered Trademarks
[Class : 5] Medicinal And Pharmaceutical Preparations And Substances
[Class : 5] Medicinal And Pharmaceutical Preparations And Substances
[Class : 5] Medicinal And Pharmaceutical Preparations And Substances
View +482 more Brands for Ipca Laboratories Limited.
Charges
02 August 2018
Citi Bank N.a.
34 Crore
01 December 2015
United Overseas Bank Limited
67 Crore
06 October 2015
Bnp Paribas
64 Crore
03 November 2014
Hsbc Bank(mauritius) Limited
124 Crore
03 May 2013
Idbi Trusteeship Services Limited
790 Crore
24 August 2011
Idbi Trusteeship Services Limited
720 Crore
24 June 2010
Kotak Mahindra Bank Limited
29 Crore
14 March 2005
Export Import Bank Of India
50 Lak
10 February 2005
Citicorp Finance (india) Ltd.
4 Lak
26 September 2000
Export Import Bank Of India
15 Crore
05 March 1999
Icici Banking Corporation Ltd.
10 Crore
05 March 1999
Icici Banking Corporation Ltd.
10 Crore
20 April 1998
Export - Import Bank Of India
4 Crore
16 October 1991
Canara Bank
3 Crore
06 October 1991
Canara Bank
3 Crore
02 November 1989
The Icici Bank Ltd.
1 Crore
11 October 1989
Canara Bank
7 Crore
01 June 1989
Canara Bank
75 Lak
14 March 1989
Icici Bank Ltd.
1 Crore
04 January 1989
Canara Bank
2 Crore
11 October 1987
Canara Bank
9 Crore
24 January 1986
Canara Bank
75 Lak
28 June 1985
Canara Bank
84 Lak
29 June 1981
Canara Bank
5 Lak
20 August 1979
Canara Bank
30 Lak
31 March 1978
Canara Bank
5 Lak
07 February 1977
Canara Bank
2 Lak
14 December 1972
Canara Bank
2 Lak
22 October 1970
Canara Bank
1 Lak
26 December 1968
Mahrashtra State Financial Corporation
3 Lak
02 May 1968
Canara Bank
50 Thousand
08 May 1967
Maharashtra State Financial Corporation
2 Lak
23 June 1966
Canara Bank
1 Lak
01 February 1961
Mercatile Bank Ltd.
1 Lak
05 June 2014
Hsbc Bank(mauritius) Limited
125 Crore
06 February 2017
St Helen's Nominees India Private Limited
68 Crore
28 December 2015
Standard Chartered Bank
17 Crore
28 August 2013
Dbs Bank Ltd.
64 Crore
15 February 2013
Hsbc Bank(mauritius) Limited
65 Crore
09 January 2013
Idbi Trusteeship Services Limited
5 Crore
06 November 2007
Bnp Paribas
61 Crore
18 November 2011
Hsbc Bank(mauritius) Limited
90 Crore
28 March 2011
Barclays Bank Plc
50 Crore
24 August 2011
Idbi Trusteeship Services Limited
15 Crore
17 May 2010
Dbs Bank Ltd
45 Crore
02 February 2010
Citi Bank N.a.
25 Crore
08 December 2011
Idbi Trusteeship Services Limited
50 Crore
11 October 1989
Canara Bank
650 Crore
24 February 2009
Idbi Trusteeship Services Limited
50 Crore
14 October 2009
Kotak Mahindra Bank Limited
22 Crore
26 June 2007
Unit Trust Of India Investment Advisory Services Limited
48 Crore
13 March 2009
Bank Of Baroda
15 Crore
15 November 2007
Hdfc Bank Limited
40 Crore
09 November 1994
Bank Of Baroda
31 Crore
06 March 2003
Bank Of Baroda
31 Crore
23 September 2004
Icici Bank Ltd.
1 Crore
17 May 2004
Cooperative Centrale Raiffeisenboerenleen Bank
1 Crore
26 September 2000
Export - Import Bank Of India
15 Crore
14 March 2002
Export - Import Bank Of India
50 Lak
10 August 1999
Export - Import Bank Of India
10 Crore
11 December 2003
Export - Import Bank Of India
50 Lak
25 June 2003
Export - Import Bank Of India
80 Lak
23 October 1998
Export - Import Bank Of India
3 Crore
21 September 1998
Export - Import Bank Of India
4 Crore
28 June 2000
Icici Bank Ltd.
10 Crore
12 March 2001
Icici Bank Ltd.
10 Crore
28 June 2001
Icici Bank Ltd.
5 Crore
30 March 2001
The Bank Of Nova Scotia
7 Crore
21 July 1998
Icici Bank Ltd.
10 Crore
12 September 1996
Icici Bank Ltd.
3 Crore
17 November 1995
Export - Import Bank Of India
15 Crore
29 January 1998
Export - Import Bank Of India
3 Crore
22 March 1995
Export - Import Bank Of India
10 Crore
19 October 1992
Icici Bank Ltd.
1 Lak
16 December 1997
Icici Bank Ltd.
5 Crore
11 March 1999
The Saraswat Co - Op. Bank Ltd.
22 Lak
19 March 1998
The Saraswat Co - Op. Bank Ltd.
24 Lak
08 July 1998
The Saraswat Co - Op. Bank Ltd.
16 Lak
20 November 1998
The Saraswat Co - Op. Bank Ltd.
8 Lak
17 May 1995
Corporate Bank
8 Crore
07 December 1994
Corporation Bank
4 Crore
22 January 1993
Icici Bank Ltd.
1 Crore
18 October 1993
Icici Bank Ltd.
3 Crore
06 March 1992
Icici Bank Ltd.
2 Crore
31 August 1989
Citi Bank
1 Lak
17 February 1989
Citi Bank Na
2 Lak
31 October 1990
Citi Bank Na
2 Lak
06 February 1991
Icici Bank Ltd.
1 Crore
09 May 1989
I.f.c.i. Ltd.
90 Lak
17 June 1983
Canara Bank
25 Lak
07 February 1983
Canara Bank
9 Lak
06 October 1983
Canara Bank
40 Lak
30 March 1987
Canara Bank
2 Crore
22 November 1980
Canara Bank
8 Lak
15 November 1984
Karnataka Bank Ltd.
25 Lak
03 December 1974
Canara Bank
5 Lak
20 December 1978
Canara Bank
5 Lak
21 November 1969
Canara Bank
50 Thousand
18 October 1973
Canara Bank
4 Lak
20 October 1976
Canara Bank
2 Lak
18 March 1974
Canara Bank
40 Lak
29 August 2023
Hdfc Bank Limited
0
08 August 2023
The Hongkong And Shanghai Banking Corporation Limited
0
07 October 2022
Hdfc Bank Limited
0
02 August 2022
Jp Morgan Chase Bank, N.a.
0
11 March 2022
Others
0
25 March 2022
Others
0
03 November 2014
Hsbc Bank(mauritius) Limited
0
02 August 2018
Citi Bank N.a.
0
25 June 2003
Export - Import Bank Of India
0
06 March 2003
Bank Of Baroda
0
18 March 1974
Canara Bank
0
17 February 1989
Citi Bank Na
0
31 October 1990
Citi Bank Na
0
19 October 1992
Icici Bank Ltd.
0
22 January 1993
Icici Bank Ltd.
0
18 October 1993
Icici Bank Ltd.
0
07 December 1994
Corporation Bank
0
22 March 1995
Export - Import Bank Of India
0
17 May 1995
Corporate Bank
0
12 September 1996
Icici Bank Ltd.
0
16 December 1997
Icici Bank Ltd.
0
29 January 1998
Export - Import Bank Of India
0
19 March 1998
The Saraswat Co - Op. Bank Ltd.
0
08 July 1998
The Saraswat Co - Op. Bank Ltd.
0
21 July 1998
Icici Bank Ltd.
0
23 October 1998
Export - Import Bank Of India
0
20 November 1998
The Saraswat Co - Op. Bank Ltd.
0
11 March 1999
The Saraswat Co - Op. Bank Ltd.
0
28 June 2000
Icici Bank Ltd.
0
12 March 2001
Icici Bank Ltd.
0
28 June 2001
Icici Bank Ltd.
0
09 January 2013
Idbi Trusteeship Services Limited
0
23 September 2004
Icici Bank Ltd.
0
06 February 2017
Others
0
26 June 2007
Unit Trust Of India Investment Advisory Services Limited
0
28 March 2011
Barclays Bank Plc
0
24 August 2011
Idbi Trusteeship Services Limited
0
18 November 2011
Hsbc Bank(mauritius) Limited
0
03 May 2013
Idbi Trusteeship Services Limited
0
05 June 2014
Hsbc Bank(mauritius) Limited
0
06 October 2015
Bnp Paribas
0
28 December 2015
Standard Chartered Bank
0
09 November 1994
Bank Of Baroda
0
22 October 1970
Canara Bank
0
11 October 1989
Canara Bank
0
14 March 2005
Export Import Bank Of India
0
01 February 1961
Mercatile Bank Ltd.
0
02 May 1968
Canara Bank
0
26 December 1968
Mahrashtra State Financial Corporation
0
14 December 1972
Canara Bank
0
20 October 1976
Canara Bank
0
07 February 1977
Canara Bank
0
20 August 1979
Canara Bank
0
29 June 1981
Canara Bank
0
07 February 1983
Canara Bank
0
17 June 1983
Canara Bank
0
30 March 1987
Canara Bank
0
11 October 1987
Canara Bank
0
14 March 1989
Icici Bank Ltd.
0
01 June 1989
Canara Bank
0
31 August 1989
Citi Bank
0
06 October 1991
Canara Bank
0
16 October 1991
Canara Bank
0
06 March 1992
Icici Bank Ltd.
0
17 November 1995
Export - Import Bank Of India
0
21 September 1998
Export - Import Bank Of India
0
10 August 1999
Export - Import Bank Of India
0
26 September 2000
Export - Import Bank Of India
0
30 March 2001
The Bank Of Nova Scotia
0
14 March 2002
Export - Import Bank Of India
0
11 December 2003
Export - Import Bank Of India
0
17 May 2004
Cooperative Centrale Raiffeisenboerenleen Bank
0
06 November 2007
Bnp Paribas
0
15 November 2007
Hdfc Bank Limited
0
24 February 2009
Idbi Trusteeship Services Limited
0
13 March 2009
Bank Of Baroda
0
14 October 2009
Kotak Mahindra Bank Limited
0
02 February 2010
Citi Bank N.a.
0
17 May 2010
Dbs Bank Ltd
0
24 June 2010
Kotak Mahindra Bank Limited
0
24 August 2011
Idbi Trusteeship Services Limited
0
08 December 2011
Idbi Trusteeship Services Limited
0
15 February 2013
Others
0
28 August 2013
Dbs Bank Ltd.
0
01 December 2015
United Overseas Bank Limited
0
10 February 2005
Citicorp Finance (india) Ltd.
0
21 November 1969
Canara Bank
0
05 March 1999
Icici Banking Corporation Ltd.
0
26 September 2000
Export Import Bank Of India
0
23 June 1966
Canara Bank
0
18 October 1973
Canara Bank
0
03 December 1974
Canara Bank
0
31 March 1978
Canara Bank
0
20 December 1978
Canara Bank
0
22 November 1980
Canara Bank
0
06 October 1983
Canara Bank
0
15 November 1984
Karnataka Bank Ltd.
0
28 June 1985
Canara Bank
0
24 January 1986
Canara Bank
0
04 January 1989
Canara Bank
0
09 May 1989
I.f.c.i. Ltd.
0
11 October 1989
Canara Bank
0
02 November 1989
The Icici Bank Ltd.
0
06 February 1991
Icici Bank Ltd.
0
20 April 1998
Export - Import Bank Of India
0
05 March 1999
Icici Banking Corporation Ltd.
0
08 May 1967
Maharashtra State Financial Corporation
0
29 August 2023
Hdfc Bank Limited
0
08 August 2023
The Hongkong And Shanghai Banking Corporation Limited
0
07 October 2022
Hdfc Bank Limited
0
02 August 2022
Jp Morgan Chase Bank, N.a.
0
11 March 2022
Others
0
25 March 2022
Others
0
03 November 2014
Hsbc Bank(mauritius) Limited
0
02 August 2018
Citi Bank N.a.
0
25 June 2003
Export - Import Bank Of India
0
06 March 2003
Bank Of Baroda
0
18 March 1974
Canara Bank
0
17 February 1989
Citi Bank Na
0
31 October 1990
Citi Bank Na
0
19 October 1992
Icici Bank Ltd.
0
22 January 1993
Icici Bank Ltd.
0
18 October 1993
Icici Bank Ltd.
0
07 December 1994
Corporation Bank
0
22 March 1995
Export - Import Bank Of India
0
17 May 1995
Corporate Bank
0
12 September 1996
Icici Bank Ltd.
0
16 December 1997
Icici Bank Ltd.
0
29 January 1998
Export - Import Bank Of India
0
19 March 1998
The Saraswat Co - Op. Bank Ltd.
0
08 July 1998
The Saraswat Co - Op. Bank Ltd.
0
21 July 1998
Icici Bank Ltd.
0
23 October 1998
Export - Import Bank Of India
0
20 November 1998
The Saraswat Co - Op. Bank Ltd.
0
11 March 1999
The Saraswat Co - Op. Bank Ltd.
0
28 June 2000
Icici Bank Ltd.
0
12 March 2001
Icici Bank Ltd.
0
28 June 2001
Icici Bank Ltd.
0
09 January 2013
Idbi Trusteeship Services Limited
0
23 September 2004
Icici Bank Ltd.
0
06 February 2017
Others
0
26 June 2007
Unit Trust Of India Investment Advisory Services Limited
0
28 March 2011
Barclays Bank Plc
0
24 August 2011
Idbi Trusteeship Services Limited
0
18 November 2011
Hsbc Bank(mauritius) Limited
0
03 May 2013
Idbi Trusteeship Services Limited
0
05 June 2014
Hsbc Bank(mauritius) Limited
0
06 October 2015
Bnp Paribas
0
28 December 2015
Standard Chartered Bank
0
09 November 1994
Bank Of Baroda
0
22 October 1970
Canara Bank
0
11 October 1989
Canara Bank
0
14 March 2005
Export Import Bank Of India
0
01 February 1961
Mercatile Bank Ltd.
0
02 May 1968
Canara Bank
0
26 December 1968
Mahrashtra State Financial Corporation
0
14 December 1972
Canara Bank
0
20 October 1976
Canara Bank
0
07 February 1977
Canara Bank
0
20 August 1979
Canara Bank
0
29 June 1981
Canara Bank
0
07 February 1983
Canara Bank
0
17 June 1983
Canara Bank
0
30 March 1987
Canara Bank
0
11 October 1987
Canara Bank
0
14 March 1989
Icici Bank Ltd.
0
01 June 1989
Canara Bank
0
31 August 1989
Citi Bank
0
06 October 1991
Canara Bank
0
16 October 1991
Canara Bank
0
06 March 1992
Icici Bank Ltd.
0
17 November 1995
Export - Import Bank Of India
0
21 September 1998
Export - Import Bank Of India
0
10 August 1999
Export - Import Bank Of India
0
26 September 2000
Export - Import Bank Of India
0
30 March 2001
The Bank Of Nova Scotia
0
14 March 2002
Export - Import Bank Of India
0
11 December 2003
Export - Import Bank Of India
0
17 May 2004
Cooperative Centrale Raiffeisenboerenleen Bank
0
06 November 2007
Bnp Paribas
0
15 November 2007
Hdfc Bank Limited
0
24 February 2009
Idbi Trusteeship Services Limited
0
13 March 2009
Bank Of Baroda
0
14 October 2009
Kotak Mahindra Bank Limited
0
02 February 2010
Citi Bank N.a.
0
17 May 2010
Dbs Bank Ltd
0
24 June 2010
Kotak Mahindra Bank Limited
0
24 August 2011
Idbi Trusteeship Services Limited
0
08 December 2011
Idbi Trusteeship Services Limited
0
15 February 2013
Others
0
28 August 2013
Dbs Bank Ltd.
0
01 December 2015
United Overseas Bank Limited
0
10 February 2005
Citicorp Finance (india) Ltd.
0
21 November 1969
Canara Bank
0
05 March 1999
Icici Banking Corporation Ltd.
0
26 September 2000
Export Import Bank Of India
0
23 June 1966
Canara Bank
0
18 October 1973
Canara Bank
0
03 December 1974
Canara Bank
0
31 March 1978
Canara Bank
0
20 December 1978
Canara Bank
0
22 November 1980
Canara Bank
0
06 October 1983
Canara Bank
0
15 November 1984
Karnataka Bank Ltd.
0
28 June 1985
Canara Bank
0
24 January 1986
Canara Bank
0
04 January 1989
Canara Bank
0
09 May 1989
I.f.c.i. Ltd.
0
11 October 1989
Canara Bank
0
02 November 1989
The Icici Bank Ltd.
0
06 February 1991
Icici Bank Ltd.
0
20 April 1998
Export - Import Bank Of India
0
05 March 1999
Icici Banking Corporation Ltd.
0
08 May 1967
Maharashtra State Financial Corporation
0
Documents
Form MSME FORM I-29042024_signed
Form MGT-6-23012024_signed
Optional Attachment-(2)-23012024
Optional Attachment-(1)-23012024
-23012024
Form MSME FORM I-08122023_signed
Form MSME FORM I-21112023_signed
Form MSME FORM I-09112023_signed
Form MSME FORM I-30102023
Form Addendum to AOC-4 CSR-21102023_signed
Form AOC-4(XBRL)-17102023-signed
Shareholders_List_F65113813_HPKAMATH01_20231011101912.xlsm
Optional Attachment-(2)-26092023
Copy of MGT-8-26092023
Optional Attachment-(1)-26092023
Form MGT-7-26092023_signed
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-07092023
Optional Attachment-(1)-07092023
XBRL document in respect Consolidated financial statement-07092023
Form MGT-15-06092023_signed
Optional Attachment-(1)-06092023
Form MGT-6-02092023_signed
Form MSME FORM I-29082023_signed
Form MGT-6-26082023_signed
Form MGT-6-09022023
Form MGT-6-16062023_signed
Optional Attachment-(2)-16062023
Optional Attachment-(1)-16062023
-16062023
Optional Attachment-(3)-16062023
